Elan Shares Climb on $3.25B Biogen's Tysabri Deal
Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
CIBC's Tal: We Need to Monitor Subprime Loans in Canada
27:34 - According to the latest report from CMHC, condo building activity in Toronto appears to be "well managed," unlike the 1980s housing bubble. Yet, BOC Governor Stephen Poloz recently addressed the pace of rising home prices in Canada's two hottest markets - Toronto and Vancouver. Benjamin Tal, deputy chief economist at CIBC World Markets, joins Bloomberg TV Canada's Amanda Lang to discuss the current state of the Canadian housing market, where it's headed and what measures need to be taken to "cool" foreign buyers. (Source: Bloomberg)